NEW YORK (TheStreet) -- Dyax Corp
(DYAX) shares are jumping, up 25% to $8.25, on Tuesday after rival Biocryst
(BCRX) reported positive findings in the clinical trial for its hereditary angioedema (HAE) drug BCX416.
Investors have reacted positively to the news as it bodes well for Dyax's alternative HAE treatment DX-2930, which is currently being developed as a prophylactic HAE treatment.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts